Citadel Advisors
CTMX icon

Citadel Advisors’s CytomX Therapeutics CTMX Stock Holding History

Citadel Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
88,600
-267,800
-75% -$1.02M ﹤0.01% 10896
2026
Q1 		$1.68M Buy
356,400
+305,200
+596% +$1.55M ﹤0.01% 6477
2025
Q4 		$218K Buy
51,200
+7,700
+18% +$29.3K ﹤0.01% 10854
2025
Q3 		$139K Sell
43,500
-62,500
-59% -$141K ﹤0.01% 11595
2025
Q2 		$241K Buy
106,000
+58,100
+121% +$93.7K ﹤0.01% 10296
2025
Q1 		$30.5K Buy
47,900
+43,200
+919% +$33.5K ﹤0.01% 12807
2024
Q4 		$4.84K Sell
4,700
-3,600
-43% -$3.87K ﹤0.01% 13901
2024
Q3 		$9.79K Buy
8,300
+700
+9% +$889 ﹤0.01% 13237
2024
Q2 		$9.27K Buy
7,600
+3,100
+69% +$6.17K ﹤0.01% 13146
2024
Q1 		$9.81K Buy
4,500
+1,300
+41% +$2.4K ﹤0.01% 13481
2023
Q4 		$4.96K Sell
3,200
-200
-6% -$263 ﹤0.01% 13466
2023
Q3 		$4.39K Sell
3,400
-7,200
-68% -$11.3K ﹤0.01% 13488
2023
Q2 		$18.2K Buy
10,600
+3,000
+39% +$4.98K ﹤0.01% 12812
2023
Q1 		$11.5K Buy
7,600
+3,000
+65% +$6.78K ﹤0.01% 13475
2022
Q4 		$7.36K Buy
+4,600
New +$6.81K ﹤0.01% 13829
2022
Q2 		– Sell
-11,400
Closed -$30K – 13020
2022
Q1 		$30K Sell
11,400
-31,300
-73% -$120K ﹤0.01% 13101
2021
Q4 		$185K Buy
42,700
+32,400
+315% +$190K ﹤0.01% 11958
2021
Q3 		$52K Sell
10,300
-8,500
-45% -$45.5K ﹤0.01% 13349
2021
Q2 		$119K Sell
18,800
-5,800
-24% -$45.2K ﹤0.01% 12748
2021
Q1 		$190K Buy
+24,600
New +$195K ﹤0.01% 11761

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors's CTMX Position: Q2 2026 in Review

Citadel Advisors reduced its CytomX Therapeutics (CTMX) stake by 42% in Q2 2026, selling an estimated $8.77M and leaving 3,110,509 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Citadel Advisors first reported a position in CTMX in Q1 2017 and has held it in 33 quarters since. The position peaked at $25.4M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Citadel Advisors held 3,110,509 shares of CytomX Therapeutics worth $11.7M as of Q2 2026.
  • Citadel Advisors sold 2,295,684 CytomX Therapeutics shares in Q2 2026, an estimated $8.77M.
  • CytomX Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3330 holding.
  • Citadel Advisors first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 33 quarters since.
  • Citadel Advisors's CytomX Therapeutics position peaked at $25.4M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.